Oral session:
- Baseline Characteristics and Results of the Phase 2 COG1201 SHIMMER Study of Zervimesine (CT1812)
Poster Presentations:
- Zervimesine (CT1812) Treatment Benefits Patients with Lower Baseline Plasma p-tau217 Across the Mild-to-Moderate AD Spectrum
- Exploratory CSF proteomic analysis of a pre-specified pTau217 subgroup from the SHINE clinical trial identifies biomarkers correlated with cognitive improvement in Alzheimer’s disease patients treated with zervimesine
- Plasma proteomic analysis of a biomarker-defined subpopulation in the SHINE Ph2 trial to identify molecular correlates to the favorable decrease in the neuroinflammatory marker GFAP with zervimesine in Alzheimer’s disease participants